secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001193125-22-061308
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director H. Thomas Watkins to resign; executive compensation and equity grants for 2022
--------------------------------------------------------------------------------

- H. Thomas Watkins, director since 2006, will resign at 2022 Annual Meeting; board to shrink from 6 to 5.
- CEO Mihael Polymeropoulos awarded 2021 bonus of $596,744; 2022 base salary $815,140 and target bonus 80%.
- 2022 option grants at $11.36/share: CEO receives 275,000 options and 115,000 RSUs.
- CFO Kevin Moran 2021 bonus $175,473; 2022 base $426,120 and target 45%; option for 77,500 shares.
- Aranthan Jones resigned as Chief Corporate Affairs Officer effective Oct 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312522061308/0001193125-22-061308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312522061308/d287693d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-061308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer